Androgen therapy and atherosclerotic cardiovascular disease

Vascular Health and Risk Management

Volumn 4, Issue 1, 2008, Pages 11-21

  McGrath, K C Y ^a   McRobb, L S ^a,b   Heather, Alison K ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CETRORELIX; ESTRADIOL; ESTROGEN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; NANDROLONE; PRASTERONE; STANOZOLOL; TESTOSTERONE;

AGING; ANDROGEN THERAPY; APLASTIC ANEMIA; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORRELATIONAL STUDY; DIABETES MELLITUS; GENETIC SUSCEPTIBILITY; HEART PROTECTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; SEX DIFFERENCE;

ANDROGENS; ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; RISK FACTORS;

EID: 41549113825     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2008.04.01.11     Document Type: Review

References (89)

1. Adams MR, Williams JK, Kaplan JR. 1995. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vase Biol, 15:562-70.
2. Alexandersen P, Haarbo J, Byrjalsen I, et al. 1999. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res, 84:813-19.
3. Andersson B, Mattsson LA, Hahn L, et al. 1997. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 82:638-43.
4. Arad Y, Badimon JJ, Badimon L, et al. 1989. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbits. Arteriosclerosis, 9:159-65.
5. Barrett-Connor E, Khaw KT. 1988. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation, 78:539-45.
6. Benton WPM, Guo Z, Krucken J, Wunderlich F. 2004. Rapid effects of androgens in macrophages. Steroids, 69:585-90.
7. Bjorntorp P. 1993. Hyperandrogenicity in women-a prediabetic condition? J Intern Med, 234:579-83.
8. Bonithon-Kopp C, Scarabin PY, Bara L, et al. 1988. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis, 71:71-6.
9. Bruck B, Brehme U, Gugel N, et al. 1997. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vase Biol, 17:2192-9.
10. Chen SJ, Li HB, Durand J, et al. 1996. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation, 93:577-84.
11. Contoreggi CS, Blackman MR, Andres R, et al. 1990. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl, 11:460-70.
12. Cooper BC, Gokina NI, Osol G. 2007. Testosterone replacement increases vasodilatory reserve in androgen-deficient female rats. Fertility and Sterility, 87:422-5.
13. Davison SL, Bell R. 2006. Androgen physiology. Seminars in Reproductive Medicine, 24:71-7.
14. Death AK, McGrath KCY, Sader MA, et al. 2004. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-(B-dependent pathway. Endocrinology, 145:1889-97.
15. Eich DM, Nestler JE, Johnson DE, et al. 1993. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation, 87:261-5.
16. Elhage R, Arnal JF, Pieraggi MT, et al. 1997. 17(-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 17:2679-84.
17. English KM, Mandour O, Steeds RP, et al. 2000. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 21:890-4.
18. English KM, Steeds RP, Jones TH, et al. 2000. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation, 102:1906-11.
19. Fogelberg M BI, Dicsfalusy U, Henriksson P. 1990. Stanozolol and experimental atherosclerosis: atherosclerosis development and blood lipids during anabolic steroid therapy of New Zealand white rabbits. Scand J Clin Lan Invest, 50:693-700.
20. Friedl R, Brunner M, Moeslinger T, et al. 2000. Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages. Life Sci, 68:417-29.
21. Fujimoto R, Morimoto I, Morita E, et al. 1994. Androgen receptors, 5(- reductase activity and androgen-dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol, 50:169-74.
22. Gioeli D, Ficarro SB, Kwiek JJ, et al. 2002. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. Journal of Biological Chemistry, 277:29304-14.
23. Gordon GB, Bush DE, Weisman HF. 1988, Reduction of atherosclerosis by administration of dehydroepiandrosterone: a study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest, 82:58-64.
24. Gordon T, Castelli WP, Hjortland MC, et al. 1997. High density lipoprotein as a protective factor against coronary artery disease: the Framingham Study. Am J Med, 62:707-14.
25. Grino PB, Griffin JE, Wilson JD. 1990. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology, 126:1165-72.
26. Haddad RM, Kennedy CC, Caples SM, et al. 2007. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled studies. Mayo Clinic Proc, 82:29-39.
27. Haffner SM, Shaten J, Stern MP, et al. 1996. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. American Journal of Epidemiology, 143:889-97.
28. Hak AE, Witteman JC, de Jong FH, et al. 2002. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab, 87:3632-9.
29. Hartgens F, Rietjens G, Keizer HA, et al. 2004. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).. Br J Sports Med, 38:253-9.
30. Hashimura K, Sudhir K, Nigro J, et al. 2005. Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increases lipoprotein binding. Endocrinology, 146:2085-90.
31. Hatakeyama H, Nishizawa M, Nakagawa A, et al. 2002. Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Letters, 530:129-32.
32. Hawk T, Zhang YQ, Rajakumar G, et al. 1998. Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res, 796:296-8.
33. Holmang A, Svedberg J, Jennische E, et al. 1990. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol, 259:E555-60.
34. Hougaku H, Fleg JL, Najjar SS, et al. 2006. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab, 290:E234-42.
35. Isidori AM, Giannetta E, Pozza C, et al. 2005. Androgens, cardiovascular disease and osteoporosis. Journal of Endocrinological Investigation, 28:73-9.
36. Jeanes H, Newby D, Gray GA. 2007. Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches. Expert Opinion on Pharmacotherapy, 8:279-88.
37. Jenkins C, Salisbury R, Ely D. 1994. Castration lowers and testosterone restores blood pressure in several rat strains on high sodium diet. Clin Exp Hypertens, 16:611-25.
38. Kalin MF, Zumoff B. 1999. Sex hormones and coronary disease: a review of the clinical studies. Steroids, 55:330-52.
39. Khaw KT, Barrett-Connor E. 1992. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol, 2:675-82.
40. Korytkowski MT, Krug EI, Daly MA, et al. 2005. Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes?. Metabolism Clinical and Experimental, 54:1626-31.
41. Krentz; AJ, von Muhlen D, Barrett-Connor E. 2007. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause, 14:284-92.
42. Krongrad A, Wilson CM, Wilson JD, et al. 1991. Androgens increase androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Molecular and Cellular Endocrinology, 76:79-88.
43. Kupelian V, Page ST, Araujo AB, et al. 2006. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol and Metab, 91:843-50.
44. Langer C, Gansz B, Goepfert C, et al. 2002. Testosterone up-regulates scavenger receptor B1 and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun, 296:1051-7.
45. Larsen BA, Nordestgaard BG, Stender S, et al. 1993. Effect of T on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis, 99:79-86.
46. Lee HJ, Chang C. 2002. Recent advances in androgen receptor action. Cellular and Molecular Life Sciences, 60:1613-22.
47. Ling S, Dai A, Dilley RJ, et al. 2004. Endogenous estrogen deficiency reduces proliferation and enhances apoptosis-related death in vascular smooth muscle cells: insights from the aromatase knock-out mouse. Circulation, 539-43.
48. Liu PY, Death AK, Handelsman DJ. 2003. Androgens and Cardiovascular disease. Endocrine Reviews, 24:313-40.
49. Malkin CJ, Pugh PJ, Jones TH, Channer KS. 2003. Testosterone for secondary prevention in men with ischaemic heart disease. Quart J Med, 96:521-9.
50. Malkin CJ, Jones RD, Jones TH, Channer KS. 2006. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci, 111:265-74.
51. Malkin CJ, Pugh PJ, West JN, et al. 2006. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J, 27:57-64.
52. Marin P, Holmang S, Jonsson L, et al. 1992. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord, 16:991-7.
53. Maron BJ, Shirani J, Poliac LC, et al. 1996. Sudden death in young competitive athletes Clinical, demographic and pathological profiles. JAMA, 276:199-204.
54. Meriggiola MC, Marcovina S, Paulsen CA, et al. 1995. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl, 18:237-42.
55. Mukherjee TK, Dinh H, Chaudhuri G, et al. 2002. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. PNAS, 99:4055-60.
56. Muller M, van den Beld AW, Bots ML, et al. 2004. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation, 109:2074-9.
57. Nathan L, Shi W, Dinh H, et al. 2001. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA, 98:3589-93.
58. Ng M, Quinn CM, McCrohon JA, et al. 2003. Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol, 42:1306-13.
59. Obasanjo IO, Clarkson TB, Weaver DS. 1996. Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism, 45:463-8.
60. Page ST, Amory JK, Bowman FD, et al. 2005. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab, 90:1502-10.
61. Paradisi G, Steinberg HO, Hempfling A, et al. 2001. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 103:1410-15.
62. Polderman KH, Gooren LJ, Asscheman H, et al. 1994. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab, 79:265-71.
63. Pugh PJ, Jones TH, Channer KS. 2003. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J, 24:909-15.
64. Quigley CA, DeBellis A, Marschke KB, et al. 1995. Androgen receptor defects: historical, clinical and molecular perspectives. Endocrinology Reviews, 16:271-321.
65. Reckelhoff JF. 2005. Sex steroids, cardiovascular disease and hypertension. Hypertension, 45:170-4.
66. Rosano GM, Leonardo F, Pagnotta P, et al. 1990. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation, 99:1666-70.
67. Ross R. 1999. Atherosclerosis- an inflammatory disease. N Engl J Med, 340:115-26.
68. Rossouw JE, Prentice RL, Manson JE, Wu L, et al. 2007. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297:1465-77.
69. Seyrek M, Yildiz O, Ulusoy HB, Yildrim V. 2007. Testosterone relaxes isolated human radial artery by potassium channel opening action. J Pharmocological Sciences, 103:309-16.
70. Snyder PJ, Peachey H, Berlin JA, et al. 2001. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med, 111:255-60.
71. Stellato RK, Feldman HA, Hamby O, et al. 2000. Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle aged men. Diabetes Care, 23:490-4.
72. Svartberg J, von Muhlen D, Schirmer H, et al. 2004. Association of endogenous testosterone with blood pressure and left ventricular mass in men: the Tromso Study. Eur J Endocrinol, 150:65-71.
73. Tchernof A, Labrie F, Belanger A, et al. 1997. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis, 133:235-44.
74. Thomas H, Dadgar N, Aphale A, et al. 2004. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to an expanded glutamine tracts. Journal of Biological Chemistry, 279:8389-95.
75. Toda T, Toda Y, Cho BH, et al. 1984. Ultrastructural changes in the comb and aorta of chicks fed excess testosterone. Arteriosclerosis, 51:47-53.
76. Tracy RE. 1966. Sex differences in coronary disease: two opposing views. J Chronic Dis, 19:1245-51.
77. Trapman J, Ris-Stalpers C, van der Korput JA, et al. 1990. The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. Journal of Steroid Biochemistry and Molecular Biology, 37:837-42.
78. van Kesteren P, Asschemen H, Megens JAJ, et al. 1997. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol, 47:337-42.
79. Vermeulen A, Kaufman JM, 2002. Diagnosis of hypogonadism in the aging male. Aging Male, 5:270-6.
80. von Dehn G, von Dehn O, Volker W, et al. 2001. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res, 33:110-4.
81. Webb CM, Adamson DL, de Zeigler D, et al. 1999. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease Am J Cardiol, 83:437-9.
82. Whitsel EA, Boyko EJ, Matsumoto AM, et al. 2001. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med, 111:261-9.
83. Wierman ME. 2007. Sex steroid effects at target tissues: mechanisms of action. Advances in Physiology Education, 31:26-33.
84. Woodard TL, Burghen GA, Kitabchi AE, Wilimas JA. 1981. Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone. J Clin Endocrinol Metab, 53:905-8.
85. Wu FC, Farley TM, Peregoudov A, Waites GM. 1996. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril, 65:626-36.
86. Wu FC, von Eckardstein A. 2003. Androgens and coronary artery disease. Endocrine Reviews, 24:183-217.
87. Yeap BB, Krueger RG, Leedman PJ. 1999. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology, 140:3282-91.
88. Zhou ZX, Kemppainen JA, Wilson EM. 1995. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Molecular Endocrinology, 9:605-15.
89. Zmuda JM, Cauley JA, Kriska A, et al. 1997. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol, 146:609-17.